Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 3
2004 2
2005 4
2007 3
2008 5
2009 8
2010 7
2011 4
2012 5
2013 9
2014 11
2015 8
2016 14
2017 11
2018 7
2019 5
2020 4
2021 4
2022 4
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

109 results

Results by year

Filters applied: . Clear all
Page 1
Tominersen in Adults with Manifest Huntington's Disease.
McColgan P, Thobhani A, Boak L, Schobel SA, Nicotra A, Palermo G, Trundell D, Zhou J, Schlegel V, Sanwald Ducray P, Hawellek DJ, Dorn J, Simillion C, Lindemann M, Wheelock V, Durr A, Anderson KE, Long JD, Wild EJ, Landwehrmeyer GB, Leavitt BR, Tabrizi SJ, Doody R; GENERATION HD1 Investigators. McColgan P, et al. N Engl J Med. 2023 Dec 7;389(23):2203-2205. doi: 10.1056/NEJMc2300400. N Engl J Med. 2023. PMID: 38055260 No abstract available.
Plasma GFAP and its association with disease severity in Huntington's disease.
Tan K, Alpaugh M, Ashton NJ, Chouinard S, Barker RA, Blennow K, Zetterberg H, Cicchetti F, Benedet AL. Tan K, et al. Among authors: chouinard s. J Neurol. 2024 Apr;271(4):2108-2113. doi: 10.1007/s00415-023-12109-y. Epub 2023 Nov 18. J Neurol. 2024. PMID: 37979092 No abstract available.
Polygenic risk score-based phenome-wide association study identifies novel associations for Tourette syndrome.
Jain P, Miller-Fleming T, Topaloudi A, Yu D, Drineas P, Georgitsi M, Yang Z, Rizzo R, Müller-Vahl KR, Tumer Z, Mol Debes N, Hartmann A, Depienne C, Worbe Y, Mir P, Cath DC, Boomsma DI, Roessner V, Wolanczyk T, Janik P, Szejko N, Zekanowski C, Barta C, Nemoda Z, Tarnok Z, Buxbaum JD, Grice D, Glennon J, Stefansson H, Hengerer B, Benaroya-Milshtein N, Cardona F, Hedderly T, Heyman I, Huyser C, Morer A, Mueller N, Munchau A, Plessen KJ, Porcelli C, Walitza S, Schrag A, Martino D; Psychiatric Genomics Consortium Tourette Syndrome Working Group (PGC-TS); EMTICS collaborative group; Dietrich A; TS-EUROTRAIN Network; Mathews CA, Scharf JM, Hoekstra PJ, Davis LK, Paschou P. Jain P, et al. Transl Psychiatry. 2023 Feb 23;13(1):69. doi: 10.1038/s41398-023-02341-5. Transl Psychiatry. 2023. PMID: 36823209 Free PMC article.
Detection of antibodies against the huntingtin protein in human plasma.
Denis HL, Alpaugh M, Alvarez CP, Fenyi A, Barker RA, Chouinard S, Arrowsmith CH, Melki R, Labib R, Harding RJ, Cicchetti F. Denis HL, et al. Among authors: chouinard s. Cell Mol Life Sci. 2023 Jan 18;80(2):45. doi: 10.1007/s00018-023-04687-x. Cell Mol Life Sci. 2023. PMID: 36651994 Free PMC article.
The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study.
Frank S, Testa C, Edmondson MC, Goldstein J, Kayson E, Leavitt BR, Oakes D, O'Neill C, Vaughan C, Whaley J, Gross N, Gordon MF, Savola JM; Huntington Study Group/ARC-HD Investigators and Coordinators. Frank S, et al. CNS Drugs. 2022 Nov;36(11):1207-1216. doi: 10.1007/s40263-022-00956-8. Epub 2022 Oct 15. CNS Drugs. 2022. PMID: 36242718 Free PMC article. Clinical Trial.
Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.
Feigin A, Evans EE, Fisher TL, Leonard JE, Smith ES, Reader A, Mishra V, Manber R, Walters KA, Kowarski L, Oakes D, Siemers E, Kieburtz KD, Zauderer M; Huntington Study Group SIGNAL investigators. Feigin A, et al. Nat Med. 2024 Feb;30(2):606. doi: 10.1038/s41591-022-02070-0. Nat Med. 2024. PMID: 36195687 Free PMC article. No abstract available.
Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.
Feigin A, Evans EE, Fisher TL, Leonard JE, Smith ES, Reader A, Mishra V, Manber R, Walters KA, Kowarski L, Oakes D, Siemers E, Kieburtz KD, Zauderer M; Huntington Study Group SIGNAL investigators. Feigin A, et al. Nat Med. 2022 Oct;28(10):2183-2193. doi: 10.1038/s41591-022-01919-8. Epub 2022 Aug 8. Nat Med. 2022. PMID: 35941373 Free PMC article. Clinical Trial.
Association of Essential Tremor With Novel Risk Loci: A Genome-Wide Association Study and Meta-analysis.
Liao C, Castonguay CE, Heilbron K, Vuokila V, Medeiros M, Houle G, Akçimen F, Ross JP, Catoire H, Diez-Fairen M, Kang J, Mueller SH, Girard SL, Hopfner F, Lorenz D, Clark LN, Soto-Beasley AI, Klebe S, Hallett M, Wszolek ZK, Pendziwiat M, Lorenzo-Betancor O, Seppi K, Berg D, Vilariño-Güell C, Postuma RB, Bernard G, Dupré N, Jankovic J, Testa CM, Ross OA, Arzberger T, Chouinard S, Louis ED, Mandich P, Vitale C, Barone P, García-Martín E, Alonso-Navarro H, Agúndez JAG, Jiménez-Jiménez FJ, Pastor P, Rajput A, Deuschl G, Kuhlenbaümer G, Meijer IA, Dion PA, Rouleau GA; 23andMe Research Team. Liao C, et al. Among authors: chouinard s. JAMA Neurol. 2022 Feb 1;79(2):185-193. doi: 10.1001/jamaneurol.2021.4781. JAMA Neurol. 2022. PMID: 34982113 Free PMC article.
Elevated common variant genetic risk for tourette syndrome in a densely-affected pedigree.
Halvorsen M, Szatkiewicz J, Mudgal P, Yu D; Psychiatric Genomics Consortium TS/OCD Working Group; Nordsletten AE, Mataix-Cols D, Mathews CA, Scharf JM, Mattheisen M, Robertson MM, McQuillin A, Crowley JJ. Halvorsen M, et al. Mol Psychiatry. 2021 Dec;26(12):7522-7529. doi: 10.1038/s41380-021-01277-w. Epub 2021 Sep 15. Mol Psychiatry. 2021. PMID: 34526668 Free PMC article.
109 results